Gaofu Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gaofu Zhang has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Qiu Li
Department of Nephrology, Children’s Hospital of Chongqing Medical University, National Clinical Research Center for Children and Adolescents’ Health and Diseases, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatric Metabolism and Inflammatory Diseases, Chongqing, People’s Republic of China
5 shared publications Ning Lan
Children's Hospital of Chongqing Medical University
4 shared publicationsXiming Xu
Children's Hospital of Chongqing Medical University
4 shared publicationsLi Wang
Department of Nephrology, Chengdu Women’s and Children’s Central Hospital, Chengdu, China
3 shared publications- Mo Wang
Department of Nephrology Children's Hospital of Chongqing Medical University, 400014, China
3 shared publications Yuhong Li
Department of Nephrology, Maternal and Child Health Hospital of Guiyang (Children’s Hospital of Guiyang), Guiyang, China
3 shared publications
Latest Publications
- Open Access
- 24 February 2026
- Published by Springer Nature in Research Square
Latent Pathogen Reactivation During Six-Monthly Rituximab Therapy in Children with Idiopathic Nephrotic Syndrome: A Retrospective Cohort Study
Background Six-monthly rituximab therapy is increasingly used to maintain remission in children with idiopathic nephrotic syndrome. Data on infection safety, particularly patterns of latent pathogen reactivation, remain limited. Methods In this retrospective, self-controlled study, 110 children with idiopathic nephrotic syndrome received rituximab (375 mg/m²) every six months. Clinical and laboratory data were collected from 12 months before to 24 months after treatment. Infection events and pathogen status were independently adjudicated by infectious disease specialists. Results During follow-up, no cases of clinically overt Epstein–Barr virus, cytomegalovirus, hepatitis B virus, or tuberculosis infection were observed. Transient and clinically silent changes in latent infection markers occurred without progression to active disease. Two patients (1.8%) developed invasive fungal pneumonia caused by Pneumocystis jirovecii or Candida albicans , both in the setting of concomitant immunosuppressive therapy. Within 12 months after rituximab initiation, 22 children (20%) experienced common infections, predominantly involving the respiratory tract. The most frequently identified pathogens were Streptococcus pneumoniae and influenza virus. In exploratory multivariable analyses, female sex and steroid-resistant nephrotic syndrome were associated with a higher risk of infection. Rituximab-associated B-cell depletion and reductions in immunoglobulin G were reversible over time, and liver and kidney function remained stable. Conclusions In this single-center cohort, a fixed six-monthly rituximab regimen was not associated with clinically significant activation of latent viral or mycobacterial infections under systematic monitoring. Respiratory infections and invasive fungal disease, particularly in the presence of concomitant immunosuppression, remain important clinical considerations.
- 24 February 2026
- Published by Springer Nature in Research Square
Open AccessLatent Pathogen Reactivation During Six-Monthly Rituximab Therapy in Children with Idiopathic Nephrotic Syndrome: A Retrospective Cohort Study
Background Six-monthly rituximab therapy is increasingly used to maintain remission in children with idiopathic nephrotic syndrome. Data on infection safety, particularly patterns of latent pathogen reactivation, remain limited. Methods In this retrospective, self-controlled study, 110 children with idiopathic nephrotic syndrome received rituximab (375 mg/m²) every six months. Clinical and laboratory data were collected from 12 months before to 24 months after treatment. Infection events and pathogen status were independently adjudicated by infectious disease specialists. Results During follow-up, no cases of clinically overt Epstein–Barr virus, cytomegalovirus, hepatitis B virus, or tuberculosis infection were observed. Transient and clinically silent changes in latent infection markers occurred without progression to active disease. Two patients (1.8%) developed invasive fungal pneumonia caused by Pneumocystis jirovecii or Candida albicans , both in the setting of concomitant immunosuppressive therapy. Within 12 months after rituximab initiation, 22 children (20%) experienced common infections, predominantly involving the respiratory tract. The most frequently identified pathogens were Streptococcus pneumoniae and influenza virus. In exploratory multivariable analyses, female sex and steroid-resistant nephrotic syndrome were associated with a higher risk of infection. Rituximab-associated B-cell depletion and reductions in immunoglobulin G were reversible over time, and liver and kidney function remained stable. Conclusions In this single-center cohort, a fixed six-monthly rituximab regimen was not associated with clinically significant activation of latent viral or mycobacterial infections under systematic monitoring. Respiratory infections and invasive fungal disease, particularly in the presence of concomitant immunosuppression, remain important clinical considerations.
- Open Access
- 17 December 2025
- Published by Springer Nature in BMC Public Health
- Vol. 26 (1)
Early warning signs and comorbidities of attention deficit hyperactivity disorder in children in Western China: a multicenter, cross-sectional study
Background: This study aimed to investigate the prevalence of attention-deficit/hyperactivity disorder (ADHD) and its association with common comorbidities among children in rural western China, to improve early recognition of ADHD in children by identifying early signs. Methods: A cross-sectional study was conducted with children aged 6–18 in rural schools across three provinces in western China. ADHD symptoms were assessed through caregiver-reported questionnaires utilizing the Swanson, Nolan, and Pelham Questionnaire-IV (SNAP-IV), without the involvement of clinical diagnosis. Propensity score matching and conditional logistic regression were used to analyze associations between ADHD risk and comorbidities while controlling for potential confounders. Results: 2.07% of children were at risk for ADHD, with only 3.25% of them receiving a diagnosis or treatment. The risk of ADHD was significantly associated with the presence of family disharmony, sleep disorders, behavioral abnormalities, and parental anxiety and depression. After matching, the strongest associations were found with abnormal behavior (OR = 6.467, P < 0.001) and daytime sleepiness (OR = 1.128, P < 0.001). Age-stratified analysis revealed that family conflict, daytime sleepiness, abnormal behavior, and parental anxiety symptoms were consistently associated with higher ADHD risk in children aged 6–15 years. Conclusions: In this cross-sectional study, the low diagnosis and treatment rates for ADHD in rural western China highlight significant gaps in recognition and intervention. Children at risk for ADHD was associated with various comorbidities, particularly behavioral abnormalities and daytime sleepiness, suggesting that screening for ADHD should be incorporated into assessments of children presenting with these comorbidities, especially in regions with low ADHD awareness.
- 17 December 2025
- Published by Springer Nature in BMC Public Health
- Vol. 26 (1)
Open AccessEarly warning signs and comorbidities of attention deficit hyperactivity disorder in children in Western China: a multicenter, cross-sectional study
Background: This study aimed to investigate the prevalence of attention-deficit/hyperactivity disorder (ADHD) and its association with common comorbidities among children in rural western China, to improve early recognition of ADHD in children by identifying early signs. Methods: A cross-sectional study was conducted with children aged 6–18 in rural schools across three provinces in western China. ADHD symptoms were assessed through caregiver-reported questionnaires utilizing the Swanson, Nolan, and Pelham Questionnaire-IV (SNAP-IV), without the involvement of clinical diagnosis. Propensity score matching and conditional logistic regression were used to analyze associations between ADHD risk and comorbidities while controlling for potential confounders. Results: 2.07% of children were at risk for ADHD, with only 3.25% of them receiving a diagnosis or treatment. The risk of ADHD was significantly associated with the presence of family disharmony, sleep disorders, behavioral abnormalities, and parental anxiety and depression. After matching, the strongest associations were found with abnormal behavior (OR = 6.467, P < 0.001) and daytime sleepiness (OR = 1.128, P < 0.001). Age-stratified analysis revealed that family conflict, daytime sleepiness, abnormal behavior, and parental anxiety symptoms were consistently associated with higher ADHD risk in children aged 6–15 years. Conclusions: In this cross-sectional study, the low diagnosis and treatment rates for ADHD in rural western China highlight significant gaps in recognition and intervention. Children at risk for ADHD was associated with various comorbidities, particularly behavioral abnormalities and daytime sleepiness, suggesting that screening for ADHD should be incorporated into assessments of children presenting with these comorbidities, especially in regions with low ADHD awareness.
- Open Access
- 1 December 2025
- Published by Springer Nature in Research Square
Risk of Reactivation of Latent Pathogens Associated with Six-Monthly Rituximab Therapy in Children with Nephrotic Syndrome: A Retrospective Cohort Study
Background Six-monthly rituximab therapy is increasingly used to maintain remission in children with idiopathic nephrotic syndrome, but evidence regarding infection safety and latent pathogen reactivation remains limited. Methods In this retrospective, self-controlled study, 110 children with idiopathic nephrotic syndrome received rituximab (375 mg/m²) every six months. Clinical and laboratory data were analyzed from 12 months before to 24 months after treatment. Infection events were independently reviewed by infectious disease specialists. Results No episodes of active Epstein Barr virus, cytomegalovirus, hepatitis B virus or tuberculosis infection occurred during follow-up. Transient, self-limited reactivations were observed without clinical progression. Two patients (1.8%) developed invasive fungal pneumonia (Pneumocystis jirovecii, Candida albicans) under concomitant immunosuppression. Within 12 months, 22 children (20%) developed mostly respiratory infections, commonly Streptococcus pneumoniae and influenza virus. Female sex and steroid-resistant nephrotic syndrome were independent risk factors. Rituximab induced B-cell depletion and immunoglobulin G reduction were reversible, with stable liver and kidney function. Conclusions In children with idiopathic nephrotic syndrome, the six-monthly rituximab regimen did not show evidence of increased activation of latent pathogens under systematic monitoring. Respiratory and fungal infections under concomitant immunosuppression remain a clinical concern. These findings offer real-world evidence to support current rituximab guidelines and may inform globally applicable strategies for infection monitoring, prophylaxis, and vaccination in children receiving biologic therapy.
- 1 December 2025
- Published by Springer Nature in Research Square
Open AccessRisk of Reactivation of Latent Pathogens Associated with Six-Monthly Rituximab Therapy in Children with Nephrotic Syndrome: A Retrospective Cohort Study
Background Six-monthly rituximab therapy is increasingly used to maintain remission in children with idiopathic nephrotic syndrome, but evidence regarding infection safety and latent pathogen reactivation remains limited. Methods In this retrospective, self-controlled study, 110 children with idiopathic nephrotic syndrome received rituximab (375 mg/m²) every six months. Clinical and laboratory data were analyzed from 12 months before to 24 months after treatment. Infection events were independently reviewed by infectious disease specialists. Results No episodes of active Epstein Barr virus, cytomegalovirus, hepatitis B virus or tuberculosis infection occurred during follow-up. Transient, self-limited reactivations were observed without clinical progression. Two patients (1.8%) developed invasive fungal pneumonia (Pneumocystis jirovecii, Candida albicans) under concomitant immunosuppression. Within 12 months, 22 children (20%) developed mostly respiratory infections, commonly Streptococcus pneumoniae and influenza virus. Female sex and steroid-resistant nephrotic syndrome were independent risk factors. Rituximab induced B-cell depletion and immunoglobulin G reduction were reversible, with stable liver and kidney function. Conclusions In children with idiopathic nephrotic syndrome, the six-monthly rituximab regimen did not show evidence of increased activation of latent pathogens under systematic monitoring. Respiratory and fungal infections under concomitant immunosuppression remain a clinical concern. These findings offer real-world evidence to support current rituximab guidelines and may inform globally applicable strategies for infection monitoring, prophylaxis, and vaccination in children receiving biologic therapy.
- 25 June 2025
- Published by Springer Nature in Pediatric Nephrology
- p. 1-14
Parental perspectives on the effectiveness and safety of rituximab in treating pediatric nephrotic syndrome: a nationwide multi-center survey study
Background Rituximab is increasingly used for steroid-dependent/frequently relapsing nephrotic syndrome, yet parental perspectives on its real-world impact remain understudied. This study evaluated parental perceptions of rituximab’s effectiveness, safety, and socioeconomic effects. Methods A nationwide cross-sectional survey was conducted across eight pediatric centers in China (Feb 2025). Validated questionnaires were administered to 570 parents of children with nephrotic syndrome, assessing rituximab efficacy, safety, financial burden, caregiver quality of life (SF-36), and treatment barriers. Multivariable regression models analyzed predictors of treatment satisfaction and parental well-being. Results Among 489 parents analyzed, 232 children (47.4%) received rituximab. Most parents (79.3%) reported good disease control, and 90.5% perceived overall improvement, with 10.3% achieving sustained complete remission without relapse after rituximab treatment. Regarding safety, 86.2% of parents observed no increase in respiratory infections, and 98.3% reported improved child quality of life. Financial burden influenced perceptions; parents from households earning < $3000 annually were less satisfied with rituximab efficacy (OR = 0.22, 95% CI: 0.08–0.60, P = 0.004). Higher SF-36 scores were reported by parents of children who discontinued steroids or had significant quality-of-life improvements. Immune suppression concerns (80.6%) and high costs remained major barriers. Conclusions This study demonstrates favorable parental perceptions of rituximab regarding efficacy, safety, and caregiver quality of life in patients with pediatric nephrotic syndrome. However, financial challenges and safety concerns limit its broader use. Policy interventions should prioritize financial subsidies, expand insurance coverage, and implement multidisciplinary support programs to address caregivers' psychosocial needs. Enhanced pre-treatment counseling and steroid-sparing protocols may further optimize parental satisfaction and treatment outcomes. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information
- 25 June 2025
- Published by Springer Nature in Pediatric Nephrology
- p. 1-14
Parental perspectives on the effectiveness and safety of rituximab in treating pediatric nephrotic syndrome: a nationwide multi-center survey study
Background Rituximab is increasingly used for steroid-dependent/frequently relapsing nephrotic syndrome, yet parental perspectives on its real-world impact remain understudied. This study evaluated parental perceptions of rituximab’s effectiveness, safety, and socioeconomic effects. Methods A nationwide cross-sectional survey was conducted across eight pediatric centers in China (Feb 2025). Validated questionnaires were administered to 570 parents of children with nephrotic syndrome, assessing rituximab efficacy, safety, financial burden, caregiver quality of life (SF-36), and treatment barriers. Multivariable regression models analyzed predictors of treatment satisfaction and parental well-being. Results Among 489 parents analyzed, 232 children (47.4%) received rituximab. Most parents (79.3%) reported good disease control, and 90.5% perceived overall improvement, with 10.3% achieving sustained complete remission without relapse after rituximab treatment. Regarding safety, 86.2% of parents observed no increase in respiratory infections, and 98.3% reported improved child quality of life. Financial burden influenced perceptions; parents from households earning < $3000 annually were less satisfied with rituximab efficacy (OR = 0.22, 95% CI: 0.08–0.60, P = 0.004). Higher SF-36 scores were reported by parents of children who discontinued steroids or had significant quality-of-life improvements. Immune suppression concerns (80.6%) and high costs remained major barriers. Conclusions This study demonstrates favorable parental perceptions of rituximab regarding efficacy, safety, and caregiver quality of life in patients with pediatric nephrotic syndrome. However, financial challenges and safety concerns limit its broader use. Policy interventions should prioritize financial subsidies, expand insurance coverage, and implement multidisciplinary support programs to address caregivers' psychosocial needs. Enhanced pre-treatment counseling and steroid-sparing protocols may further optimize parental satisfaction and treatment outcomes. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information
- Open Access
- 24 April 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-15
Systemic inflammation accelerates the development of focal segmental glomerulosclerosis in a mouse model of adriamycin induced nephrosis
Research indicates that minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) may reflect varying severities of the same underlying condition, with inflammation potentially facilitating the progression from MCD to FSGS. The aim of this study was to determine the whether systemic inflammation accelerated the progression from MCD to FSGS in a mouse model of Adriamycin-induced nephrosis. In this model, systemic inflammation induced transient proteinuria without significant serum biochemical alterations or significant renal histological changes in control mice that did not develop nephrotic syndrome. In contrast, both mice with Adriamycin-induced nephrosis mice and mice with Adriamycin-induced nephrosis with systemic inflammation showed histological features of MCD at week 4 and progressive exacerbation of FSGS. However, the glomerular lesions of mice with Adriamycin-induced nephrosis in a state of systemic inflammation were more obvious than those of mice with Adriamycin-induced nephrosis. These findings suggest that systemic inflammation may hasten histological development from MCD to FSGS in this mouse model.
- 24 April 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-15
Open AccessSystemic inflammation accelerates the development of focal segmental glomerulosclerosis in a mouse model of adriamycin induced nephrosis
Research indicates that minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) may reflect varying severities of the same underlying condition, with inflammation potentially facilitating the progression from MCD to FSGS. The aim of this study was to determine the whether systemic inflammation accelerated the progression from MCD to FSGS in a mouse model of Adriamycin-induced nephrosis. In this model, systemic inflammation induced transient proteinuria without significant serum biochemical alterations or significant renal histological changes in control mice that did not develop nephrotic syndrome. In contrast, both mice with Adriamycin-induced nephrosis mice and mice with Adriamycin-induced nephrosis with systemic inflammation showed histological features of MCD at week 4 and progressive exacerbation of FSGS. However, the glomerular lesions of mice with Adriamycin-induced nephrosis in a state of systemic inflammation were more obvious than those of mice with Adriamycin-induced nephrosis. These findings suggest that systemic inflammation may hasten histological development from MCD to FSGS in this mouse model.
- Open Access
- 31 March 2025
- Published by Springer Nature in Research Square
Parental Perspectives on the Effectiveness and Safety of Rituximab in Treating Pediatric Nephrotic Syndrome: A Nationwide Multi-Center Survey Study
Background Rituximab is increasingly used for steroid-dependent/frequently relapsing nephrotic syndrome, yet parental perspectives on its real-world impact remain understudied. This study evaluated parental perceptions of rituximab’s effectiveness, safety, and socioeconomic effects. Methods A nationwide cross-sectional survey was conducted across eight pediatric centers in China (Feb 1–15, 2025). Validated questionnaires were administered to 570 parents of children with nephrotic syndrome, assessing rituximab efficacy, safety, financial burden, caregiver quality of life (SF-36), and treatment barriers. Multivariable regression models analyzed predictors of treatment satisfaction and parental well-being. Results Among 489 parents analyzed, 232 children (47.4%) received rituximab. Most parents (79.3%) reported good disease control, and 90.5% perceived overall improvement, with 10.3% achieving complete medication discontinuation. Regarding safety, 86.2% of parents observed no increase in respiratory infections, and 98.3% reported improved child quality of life. Financial burden influenced perceptions ; parents from households earning <$30,00 annually were less satisfied with rituximab efficacy (OR = 0.22, 95% CI: 0.08–0.60, P = 0.004). Higher SF-36 scores were reported by parents of children who discontinued steroids or had significant quality-of-life improvements. Immune suppression concerns (80.6%) and high costs remained major barriers. Conclusions This study demonstrates favorable parental perceptions of rituximab regarding efficacy, safety, and caregiver quality of life in pediatric nephrotic syndrome. However, financial toxicity and safety concerns limit its broader use. Policy interventions should prioritize financial subsidies, expand insurance coverage, and implement multidisciplinary support programs to address caregivers' psychosocial needs. Enhanced pre-treatment counseling and steroid-sparing protocols may further optimize parental satisfaction and treatment outcomes.
- 31 March 2025
- Published by Springer Nature in Research Square
Open AccessParental Perspectives on the Effectiveness and Safety of Rituximab in Treating Pediatric Nephrotic Syndrome: A Nationwide Multi-Center Survey Study
Background Rituximab is increasingly used for steroid-dependent/frequently relapsing nephrotic syndrome, yet parental perspectives on its real-world impact remain understudied. This study evaluated parental perceptions of rituximab’s effectiveness, safety, and socioeconomic effects. Methods A nationwide cross-sectional survey was conducted across eight pediatric centers in China (Feb 1–15, 2025). Validated questionnaires were administered to 570 parents of children with nephrotic syndrome, assessing rituximab efficacy, safety, financial burden, caregiver quality of life (SF-36), and treatment barriers. Multivariable regression models analyzed predictors of treatment satisfaction and parental well-being. Results Among 489 parents analyzed, 232 children (47.4%) received rituximab. Most parents (79.3%) reported good disease control, and 90.5% perceived overall improvement, with 10.3% achieving complete medication discontinuation. Regarding safety, 86.2% of parents observed no increase in respiratory infections, and 98.3% reported improved child quality of life. Financial burden influenced perceptions ; parents from households earning <$30,00 annually were less satisfied with rituximab efficacy (OR = 0.22, 95% CI: 0.08–0.60, P = 0.004). Higher SF-36 scores were reported by parents of children who discontinued steroids or had significant quality-of-life improvements. Immune suppression concerns (80.6%) and high costs remained major barriers. Conclusions This study demonstrates favorable parental perceptions of rituximab regarding efficacy, safety, and caregiver quality of life in pediatric nephrotic syndrome. However, financial toxicity and safety concerns limit its broader use. Policy interventions should prioritize financial subsidies, expand insurance coverage, and implement multidisciplinary support programs to address caregivers' psychosocial needs. Enhanced pre-treatment counseling and steroid-sparing protocols may further optimize parental satisfaction and treatment outcomes.
- 15 August 2022
- Published by Elsevier in Journal of Affective Disorders
- Vol. 316, 63-70
Functional urination or defecation disorders may be warning signs of attention-deficit/hyperactivity disorder among children in rural China
- 15 August 2022
- Published by Elsevier in Journal of Affective Disorders
- Vol. 316, 63-70
Functional urination or defecation disorders may be warning signs of attention-deficit/hyperactivity disorder among children in rural China
- Open Access
The Impact of the COVID-19 Outbreak on the Medical Treatment of Chinese Children with Chronic Kidney Disease (CKD) : A Multicenter Cross-section Study in the Context of a Public Health Emergency of International Concern
Objective: To investigate the impact of the COVID-19 outbreak on the medical advice seeking of Chinese children with chronic kidney disease (CKD). Materials and Methods: An anonymous online questionnaire survey was conducted in 17 pediatric nephropathy diagnosis and treatment centers in China. The questions collected basic information on the patients and their parents and data on changes in the approach to medical treatment and their needs in the context of the outbreak etc. This is a Multicenter Cross-section Study. Results: A total of 735 valid questionnaires were collected. 555 patients (75.5%) and their parents said that the outbreak had a significant influence on their medical treatment: 264 patients (47.6%) said that it would be delayed by 2 to 4 weeks and 199 patients (35.9%) by 4 to 8 weeks. 510 patients (84.16%) hoped to get in touch with specialists through online consultation, and 528 patients (84.5%) hoped that online consultation could be implemented and that medication could be delivered to them.. A total of 458 patients (62.3%) said that their greatest concern was that the CKD would be aggravated or that they would experience a relapse; only 203 patients were infected by 2019-nCoV. A total of 313 patients (42.5%) experienced anxiety and thus required the intervention of psychologists. Conclusion: The COVID-19 outbreak has affected the medical treatment of children with CKD. Online consultation, medication delivery and psychological counselling are the greatest needs reported by patients and their families and could especially provide solutions for the management of low income children with CKD in remote rural areas in the context of the COVID-19 epidemic. Strengths and limitations of this study: The study is a Multicenter Cross-section Study in the Context of a Public Health Emergency of International Concern. The study can well explore the impact of COVID-19 outbreak on the medical treatment of CKD children in China and the needs of current patients. The study explored ways to meet the medical needs of CKD children in the context of a public health emergency of international concern, which provides a method support for all countries in the world experiencing COVID-19 outbreak. The study is an exploration of the coping strategies for CKD management in China. The limitations of this study is that it is quite simple and descriptive, and many studies need to be further carried out.
Open AccessThe Impact of the COVID-19 Outbreak on the Medical Treatment of Chinese Children with Chronic Kidney Disease (CKD) : A Multicenter Cross-section Study in the Context of a Public Health Emergency of International Concern
Objective: To investigate the impact of the COVID-19 outbreak on the medical advice seeking of Chinese children with chronic kidney disease (CKD). Materials and Methods: An anonymous online questionnaire survey was conducted in 17 pediatric nephropathy diagnosis and treatment centers in China. The questions collected basic information on the patients and their parents and data on changes in the approach to medical treatment and their needs in the context of the outbreak etc. This is a Multicenter Cross-section Study. Results: A total of 735 valid questionnaires were collected. 555 patients (75.5%) and their parents said that the outbreak had a significant influence on their medical treatment: 264 patients (47.6%) said that it would be delayed by 2 to 4 weeks and 199 patients (35.9%) by 4 to 8 weeks. 510 patients (84.16%) hoped to get in touch with specialists through online consultation, and 528 patients (84.5%) hoped that online consultation could be implemented and that medication could be delivered to them.. A total of 458 patients (62.3%) said that their greatest concern was that the CKD would be aggravated or that they would experience a relapse; only 203 patients were infected by 2019-nCoV. A total of 313 patients (42.5%) experienced anxiety and thus required the intervention of psychologists. Conclusion: The COVID-19 outbreak has affected the medical treatment of children with CKD. Online consultation, medication delivery and psychological counselling are the greatest needs reported by patients and their families and could especially provide solutions for the management of low income children with CKD in remote rural areas in the context of the COVID-19 epidemic. Strengths and limitations of this study: The study is a Multicenter Cross-section Study in the Context of a Public Health Emergency of International Concern. The study can well explore the impact of COVID-19 outbreak on the medical treatment of CKD children in China and the needs of current patients. The study explored ways to meet the medical needs of CKD children in the context of a public health emergency of international concern, which provides a method support for all countries in the world experiencing COVID-19 outbreak. The study is an exploration of the coping strategies for CKD management in China. The limitations of this study is that it is quite simple and descriptive, and many studies need to be further carried out.
- Open Access
- 17 May 2019
- Published by Springer Nature in BMC Pediatrics
- Vol. 19 (1) , 1-15
Indirect-comparison meta-analysis of treatment options for patients with refractory Kawasaki disease
There is limited information available regarding the clinical management of intravenous immunoglobulin-resistant Kawasaki disease (KD). We aimed to evaluate the optimal treatment options for patients with refractory KD by presenting an indirect-comparison meta-analysis. PubMed, EMBASE, Web of Science, and the Cochrane Database were searched on August 31, 2018. Unpublished studies were also searched in ProQuest Dissertations & Theses and through manual retrieval strategies. Randomized concurrent controlled trials (RCTs), high-quality non-randomized concurrent controlled trials (non-RCTs), and retrospective studies associated with AEs were included. The quality of all eligible studies was assessed using Cochrane collaboration’s tool and non-randomized study guidelines. Risk ratios (RR) with 95% confidence intervals (CIs) for dichotomous outcomes were estimated in our analysis. GRADE profiler 3.6.1 was used to assess the evidence profile. Twelve studies involving 372 immunoglobulin-resistant KD patients were identified and analyzed. Neither infliximab nor intravenous pulse methylprednisolone (IVMP) was significantly more effective than second IVIG infusion with respect to lowering coronary artery lesions (CALs) (infliximab, 0.85, 0.43–1.69; IVMP, 0.99, 0.52–1.88) and treatment resistance (infliximab, 0.43, 0.21–0.89; IVMP, 1.16, 0.33–4.13). No significant differences were found between infliximab and IVMP in the incidence rate of CALs (0.70, 0.27–1.81), the treatment resistance (0.37, 0.09–1.60), the rates of coronary artery aneurysm (4.13, 0.38–45.22) and the coronary artery dilatation (0.45, 0.10–1.99). Furthermore, compared with second IVIG infusion, both infliximab and IVMP showed significant effectiveness in antipyretic effects (infliximab, 1.52, 1.16–1.99; IVMP, 1.29, 0.77–2.15). However, Infliximab was noninferior to IVMP on antipyretic effects (1.18, 0.66–2.15). IVMP treatment showed significant association with fewer AEs than second IVIG infusion (0.49, 0.26–0.94) and infliximab (2.34, 1.07–5.09). No significant differences were noted between infliximab treatment and second IVIG infusion (1.06, 0.69–1.63). Infliximab, IVMP, and second IVIG infusion showed no significant differences in the cardioprotective effect or the rate of treatment resistance. Infliximab and IVMP treatment were more effective than second IVIG infusion regarding antipyretic effects. IVMP treatment may have an advantage due to its lower total rate of AEs associated with drug infusion. The study has been registered on PROSPERO ( CRD42016039693 ).
- 17 May 2019
- Published by Springer Nature in BMC Pediatrics
- Vol. 19 (1) , 1-15
Open AccessIndirect-comparison meta-analysis of treatment options for patients with refractory Kawasaki disease
There is limited information available regarding the clinical management of intravenous immunoglobulin-resistant Kawasaki disease (KD). We aimed to evaluate the optimal treatment options for patients with refractory KD by presenting an indirect-comparison meta-analysis. PubMed, EMBASE, Web of Science, and the Cochrane Database were searched on August 31, 2018. Unpublished studies were also searched in ProQuest Dissertations & Theses and through manual retrieval strategies. Randomized concurrent controlled trials (RCTs), high-quality non-randomized concurrent controlled trials (non-RCTs), and retrospective studies associated with AEs were included. The quality of all eligible studies was assessed using Cochrane collaboration’s tool and non-randomized study guidelines. Risk ratios (RR) with 95% confidence intervals (CIs) for dichotomous outcomes were estimated in our analysis. GRADE profiler 3.6.1 was used to assess the evidence profile. Twelve studies involving 372 immunoglobulin-resistant KD patients were identified and analyzed. Neither infliximab nor intravenous pulse methylprednisolone (IVMP) was significantly more effective than second IVIG infusion with respect to lowering coronary artery lesions (CALs) (infliximab, 0.85, 0.43–1.69; IVMP, 0.99, 0.52–1.88) and treatment resistance (infliximab, 0.43, 0.21–0.89; IVMP, 1.16, 0.33–4.13). No significant differences were found between infliximab and IVMP in the incidence rate of CALs (0.70, 0.27–1.81), the treatment resistance (0.37, 0.09–1.60), the rates of coronary artery aneurysm (4.13, 0.38–45.22) and the coronary artery dilatation (0.45, 0.10–1.99). Furthermore, compared with second IVIG infusion, both infliximab and IVMP showed significant effectiveness in antipyretic effects (infliximab, 1.52, 1.16–1.99; IVMP, 1.29, 0.77–2.15). However, Infliximab was noninferior to IVMP on antipyretic effects (1.18, 0.66–2.15). IVMP treatment showed significant association with fewer AEs than second IVIG infusion (0.49, 0.26–0.94) and infliximab (2.34, 1.07–5.09). No significant differences were noted between infliximab treatment and second IVIG infusion (1.06, 0.69–1.63). Infliximab, IVMP, and second IVIG infusion showed no significant differences in the cardioprotective effect or the rate of treatment resistance. Infliximab and IVMP treatment were more effective than second IVIG infusion regarding antipyretic effects. IVMP treatment may have an advantage due to its lower total rate of AEs associated with drug infusion. The study has been registered on PROSPERO ( CRD42016039693 ).